(1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid

• ChemBase编号: 73173
• 分子式: C15H28N4O4
• 平均质量: 328.40722
• 单一同位素质量: 328.2110554
• SMILES: [C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)NC(=N)N)(C(CC)CC)NC(=O)C
• Canonical SMILES: CCC([C@@H]([C@H]1[C@H](NC(=N)N)C[C@@H]([C@H]1O)C(=O)O)NC(=O)C)CC
• InChI: InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
• InChIKey: XRQDFNLINLXZLB-CKIKVBCHSA-N

名称和登记号

名称

• IUPAC标准名: (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid
• IUPAC传统名: (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid
• 别名: Peramivir

登记号

• CAS号: 229614-55-5
• PubChem SID: 162038093
• PubChem CID: 154234

理论计算性质

• Acid pKa: 4.183867
• 质子受体: 7
• 质子供体: 6
• LogD (pH = 5.5): -2.1383579
• LogD (pH = 7.4): -2.121641
• Log P: -2.1214879
• 摩尔折射率: 94.4604 cm^3
• 极化性: 33.063732 Å^3
• 极化表面积: 148.53 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: false

分子性质

安全信息

• 保存条件: -20°C

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S1822

Research Area: Infection
Biological Activity:
Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. [1] The IC50 for peramivir is markedly lower than that for either zanamivir or oseltamivir. Peramivir increases survival in preclinical influenza models, including mouse and ferret models of highly pathogenic avian influenza H5N1. One day of treatment with peramivir is active, and multiple days of treatment rescues most or all mice with H5N1. Similar data have been obtained in ongoing murine experiments with seasonal influenza A (H1N1)/H274Y. After parenteral administration, peramivir reaches very high plasma concentrations. Peramivir is not metabolized, and is cleared by the means of renal filtration. It has a long half-life, especially in comparison with other neuraminidase inhibitors. Due to the failure of the metabolism of the antivirus compound peramivir, as well as its wide distribution and the excretion in the unchanged form in urine, dosing regimens can be adapted easily for patients with renal impairment and for pediatric populations. [2] Peramivir is originally developed by BioCryst Pharmaceuticals. And peramivir is designed to aim to an antiviral agent. Peramivir has been performed phase III clinical trials for the treatment of influenza.

参考文献

• http://en.wikipedia.org/wiki/Peramivir